Home > Insider Trading > Filing (0001104659-23-124717)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1750284	Olema Pharmaceuticals Inc.	OLMA	Pharmaceutical Preparations (2834)	300409740

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1854392	Ltd. Fund International Biocapital Paradigm	767 Third Avenue, 17Th Floor New York NY 10017	No	No	Yes	No
1855655	Paradigm Biocapital Advisors Lp	767 Third Avenue, 17Th Floor New York NY 10017	No	No	Yes	No
1994082	Paradigm Biocapital Advisors Gp Llc	767 Third Avenue, 17Th Floor New York NY 10017	No	No	Yes	No
1994183	Senai Asefaw	767 Third Avenue, 17Th Floor New York NY 10017	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2023-12-06	100,000	$11.60	6,590,981	No	4	P	Indirect	By: Paradigm BioCapital International Fund Ltd.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By: Paradigm BioCapital International Fund Ltd.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	1,312,619	Indirect	By: One or more separately managed accounts

Footnotes

These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.